 |
Monday, 24 December 2001 - ASX RELEASE |
|
print 
|
Novogen has today announced that due to delays in hearing its case and the significant development progress made with its anti-cancer drug phenoxodiol, its subsidiary company MEI, has withdrawn its appeal to the stop order placed on the now superseded MEI prospectus.
|
|
|
Wednesday, 19 December 2001 - ASX RELEASE |
|
print
|
(SYDNEY, AUSTRALIA) Australian pharmaceutical company, Novogen Limited, today announced that it has been cleared to begin the fifth human trial of its experimental anti-cancer drug, phenoxodiol. An oral form of the compound will be used in patients with leukemia on the Phase Ib/IIa trial, which will be conducted at Royal North Shore Hospital, a major teaching hospital in Sydney.
|
|
|
Monday, 19 November 2001 - ASX RELEASE |
|
print
|
US CLINICAL TRIAL ON NOVOGENS EXPERIMENTAL ANTI-CANCER DRUG PHENOXODIOL TO BE EXPEDITED
|
|
|
Wednesday, 31 October 2001 - ASX RELEASE |
|
print
|
Data has been presented at a US medical conference from the first human clinical study of Novogen Limiteds novel anti-cancer drug, phenoxodiol.
|
|
|
Friday, 12 October 2001 - ASX RELEASE |
|
print
|
Novogen is now undertaking a concerted program of clinical trials. This advanced development phase has commenced with the human studies underway with phenoxodiol, the anti-cancer drug, now under clinical test at the Cleveland Clinic in the USA and at a number of hospitals in Australia.
|
|
|
Wednesday, 15 August 2001 - ASX RELEASE |
|
print
|
NOVOGEN COMMENCES CLINICAL TRIAL OF ORAL VERSION OF CANCER DRUG
|
|
|
Thursday, 26 July 2001 - ASX RELEASE |
|
print
|
This edition of the Novogen newsletter is a review of the Companys research and development activities.
|
|
|
Wednesday, 13 June 2001 |
|
print
|
AUSTRALIAN SCIENTISTS ANNOUNCE IMPORTANT CANCER DISCOVERY AT US CONFERENCE
|
|
|
Thursday, 31 May 2001 |
|
print
|
NOVOGEN RAISES $21 MILLION TO FUND PHENOXODIOL CLINICAL STUDIES
|
|
|
Monday, 28 May 2001 |
|
print
|
US CLINICAL STUDY OF NOVOGEN ANTI-CANCER DRUG PHENOXODIOL COMMENCES
|
|
|
Monday, 29 January 2001 |
|
print
|
Novogen today announced that it had received notification from the U.S. Food and Drug Administration (FDA), granting permission for the commencement in the US of human clinical testing of its anti-cancer drug phenoxodiol.
|
|
|
Monday, 08 January 2001 |
|
print
|
NOVOGENS NOVEL ANTI-CANCER DRUG RECEIVES APPROVAL TO COMMENCE SECOND CLINICAL TRIAL
|
|
|
Monday, 21 August 2000 |
|
print
|
Australian pharmaceutical company, Novogen, today announced that its anti-cancer drug, NV-06, has advanced to its next stage of clinical trialing.
|
|
|
Tuesday, 06 June 2000 |
|
print
|
Australian pharmaceutical company, Novogen Limited, today announced the completion of the first stage of Phase I clinical evaluation of its anti-cancer drug, NV-06.
|
|
|
Monday, 07 February 2000 |
|
print
|
Australian pharmaceutical company, Novogen Limited, today announced that its anti-cancer drug, NV-06, has been approved for human clinical trialing and will enter a Phase 1 trial immediately.
|
|
|
Monday, 03 January 2000 |
|
print
|
In this issue, we report progress on the three leading phenolic hormone compounds - NV-06, NV-04 and NV-07.
|
|
|
